Dorsey Wright & Associates Raises Holdings in Medpace Holdings, Inc. $MEDP

Dorsey Wright & Associates grew its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 25.5% during the 1st quarter, HoldingsChannel.com reports. The firm owned 28,140 shares of the company’s stock after acquiring an additional 5,720 shares during the quarter. Medpace makes up approximately 1.7% of Dorsey Wright & Associates’ investment portfolio, making the stock its 17th biggest position. Dorsey Wright & Associates’ holdings in Medpace were worth $13,513,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Geneos Wealth Management Inc. lifted its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Medpace in the fourth quarter worth $30,000. Elyxium Wealth LLC purchased a new position in shares of Medpace in the 4th quarter valued at $30,000. Quarry LP purchased a new position in shares of Medpace in the 3rd quarter valued at $35,000. Finally, Bayban acquired a new position in shares of Medpace during the 4th quarter valued at $44,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on MEDP. BMO Capital Markets reduced their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research note on Friday, April 24th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Medpace in a research note on Thursday, July 2nd. Royal Bank Of Canada dropped their target price on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Barclays reduced their price target on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research report on Friday, April 24th. Finally, Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Two analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $469.50.

Medpace Stock Performance

MEDP opened at $537.73 on Friday. The company has a market capitalization of $15.36 billion, a P/E ratio of 33.80, a PEG ratio of 2.69 and a beta of 1.15. The company has a 50-day moving average of $478.10 and a 200-day moving average of $494.76. Medpace Holdings, Inc. has a 1-year low of $306.70 and a 1-year high of $628.92.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.Medpace’s quarterly revenue was up 26.5% compared to the same quarter last year. During the same quarter last year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 20.50% of the stock is currently owned by insiders.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.